Mark Schoenberg - Jun 10, 2024 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Medical Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Jun 10, 2024
Transactions value $
-$67,401
Form type
4
Date filed
6/11/2024, 01:15 PM
Previous filing
Mar 20, 2024
Next filing
Sep 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +10K +7.17% 149K Jun 10, 2024 Direct F1
transaction URGN Ordinary Shares Sale -$67.4K -5.15K -3.45% $13.08 144K Jun 10, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -10K -33.33% $0.00 20K Jun 10, 2024 Ordinary Shares 10K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3 The reporting person was granted RSUs on June 8, 2023 representing 30,000 ordinary shares. The RSUs will vest in three equal annual installments from June 8, 2024.